Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213.

被引：2
|
作者：
Coleman, Robert L.
Brady, Mark F.
Herzog, Thomas J.
Armstrong, Deborah Kay
Sabbatini, Paul
Walker, Joan L.
Kim, Byoung
Fujiwara, Keiichi
Tewari, Krishnansu Sujata
O'Malley, David M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Roswell Pk Canc Inst, NRG Stat & Data Ctr, Buffalo, NY USA
[3] Univ Cincinnati, Inst Canc, Div Gynecol Oncol, Cincinnati, OH USA
[4] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Weill Cornell Med Coll, New York, NY USA
[7] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[8] Sungkyunkwan Univ, Sch Med, Dept Obstet & Gynecol, Samsung Med Ctr, Seoul, South Korea
[9] Saitama Med Univ, Int Med Ctr, Hidaka, Japan
[10] UC Irvine Med Ctr, Orange, CA USA
[11] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5523
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5523
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Gemcitabine and Vinorelbine Combination in Platinum-Sensitive Recurrent Ovarian Cancer
    Ferrero, Annamaria
    Logrippo, Vilma
    Spanu, Pier Giorgio
    Fuso, Luca
    Perotto, Stefania
    Daniele, Alberto
    Zola, Paolo
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (09) : 1529 - 1534
  • [32] Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
    Mirza, M. R.
    Monk, B. J.
    Herrstedt, J.
    Oza, A. M.
    Mahner, S.
    Redondo, A.
    Fabbro, M.
    Ledermann, J. A.
    Lorusso, D.
    Vergote, I.
    Ben-Baruch, N. E.
    Marth, C.
    Madry, R.
    Christensen, R. D.
    Berek, J. S.
    Dorum, A.
    Tinker, A. V.
    du Bois, A.
    Gonzalez-Martin, A.
    Follana, P.
    Benigno, B.
    Rosenberg, P.
    Gilbert, L.
    Rimel, B. J.
    Buscema, J.
    Balser, J. P.
    Agarwal, S.
    Matulonis, U. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22): : 2154 - 2164
  • [33] Utilization of maintenance therapy for platinum-sensitive recurrent ovarian cancer
    Wall, J. A.
    Davis, A. M.
    Beer, H.
    Foxall, M.
    Londono, A. I.
    McGwin, G.
    Leath, C. A., III
    Arend, R. C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 115 - 115
  • [34] Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC)-A real-life ambispective study.
    Ray-Coquard, Isabelle Laure
    Alexandre, Jerome
    Goldwasser, Francois
    Spano, Jean-Philippe
    Berton-Rigaud, Dominique
    Savoye, Aude-Marie
    Fabbro, Michel
    Bazan, Fernando
    Kalbacher, Elsa
    Raban, Nadia
    Giraud, Claire
    Pottier, Virginie
    Selle, Frederic
    Patsouris, Anne
    Garnier-Tixidre, Claire
    Blas, Anne Mercier
    Provencal, Jocelyne
    Brocard, Fabien
    Berdougo-Tritz, Jessica
    Launay-Vacher, Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] EFFICACY AND SAFETY OF NIRAPARIB MAINTENANCE TREATMENT IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER AFTER SHORTER OR LONGER CHEMOTHERAPY: A POST HOC SUBGROUP ANALYSIS
    Gao, Y.
    Wu, X.
    Zhu, J.
    Yin, R.
    Yang, J.
    Liu, J.
    Wang, J.
    Wu, L.
    Liu, Z.
    Wang, D.
    Lou, G.
    Yang, H.
    Zhou, Q.
    Kong, B.
    Huang, Y.
    Chen, L.
    Li, G.
    An, R.
    Tan, T.
    Dong, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A10 - A11
  • [36] Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy
    Laine, Alexandra
    Sims, Travis T.
    Le Saux, Olivia
    Ray-Coquard, Isabelle
    Coleman, Robert L.
    CURRENT ONCOLOGY REPORTS, 2021, 23 (12)
  • [37] Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy
    Alexandra Lainé
    Travis T. Sims
    Olivia Le Saux
    Isabelle Ray-Coquard
    Robert L. Coleman
    Current Oncology Reports, 2021, 23
  • [38] Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis
    Takasaki, Kazuki
    Miyamoto, Morikazu
    Takano, Masashi
    Soyama, Hiroaki
    Aoyama, Tadashi
    Matsuura, Hiroko
    Kato, Kento
    Sakamoto, Takahiro
    Kuwahara, Mika
    Iwahashi, Hideki
    Ishibashi, Hiroki
    Yoshikawa, Tomoyuki
    Furuya, Kenichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 809 - 814
  • [39] Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis
    Kazuki Takasaki
    Morikazu Miyamoto
    Masashi Takano
    Hiroaki Soyama
    Tadashi Aoyama
    Hiroko Matsuura
    Kento Kato
    Takahiro Sakamoto
    Mika Kuwahara
    Hideki Iwahashi
    Hiroki Ishibashi
    Tomoyuki Yoshikawa
    Kenichi Furuya
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 809 - 814
  • [40] EFFECTIVENESS OF BEVACIZUMAB IN PLATINUM-RESISTANT RECURRENT EPITHELIAL OVARIAN CANCER
    Pinto, R.
    Monteiro, S.
    Lima, B.
    Lopes, A. R.
    Abreu, M.
    Ferreira, M.
    Sousa, S.
    Redondo, P.
    Pereira, D.
    Savva-Bordalo, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A271 - A271
12345